Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

FasL — Too much of a good thing?

Nature Medicine volume 3, pages 727–728 (1997)Cite this article

Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system (pages 738–743).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630–632 (1995)

    Article  CAS  Google Scholar 

  2. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189–1192 (1995).

    Article  CAS  Google Scholar 

  3. Nagata, S. & Suda, T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39–43 (1995)

    Article  CAS  Google Scholar 

  4. Lau, H.T., Yu, M., Fontana, A. & Stoeckert, C.J. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109–112 (1996)

    Article  CAS  Google Scholar 

  5. Korbutt, G. S., Elliott, J. F. & Rajotte, R.V. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46, 317–322 (1997).

    Article  CAS  Google Scholar 

  6. Kang, S-M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738–743 (1997).

    Article  CAS  Google Scholar 

  7. Chervonsky, A.V. et al. The role of Fas in autoimmune diabetes. Cell 89, 17–24 (1997)

    Article  CAS  Google Scholar 

  8. Allison, J., Georgiou, H.M., Strasser, A. & Vaux, D.L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allograft. Proc. Nat. Acad. Sci. USA 94, 3943–3947 (1997).

    Article  CAS  Google Scholar 

  9. Swenson, K. et al. Fas ligand gene transfer prolongs renal allograft survival in rats. Presented at 23rd annual meeting of the American Society of Transplant Surgeons. Chicago, Illinois, May 14th, 1997.

Download references

Author information

Authors and Affiliations

  1. Department ofPediatric Surgery, The Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA

    Henry T. Lau

  2. Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

    Christian J. Stoeckert

Authors
  1. Henry T. Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian J. Stoeckert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lau, H., Stoeckert, C. FasL — Too much of a good thing?. Nat Med 3, 727–728 (1997). https://doi.org/10.1038/nm0797-727

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0797-727

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing